hasMolecularTarget
P37016
predicate
Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).
All labels observed (28)
| Label | Occurrences |
|---|---|
| targetOfDrug | 48 |
| hasMolecularTarget canonical | 28 |
| therapeuticTargetOf | 15 |
| isTargetOfDrug | 14 |
| drugTarget | 13 |
| hasPharmacologicTarget | 5 |
| isDrugTargetFor | 5 |
| isDrugTargetOf | 5 |
| isTherapeuticTargetOf | 5 |
| targetMolecule | 5 |
| drugTargetFor | 4 |
| molecularTarget | 4 |
| affectsMolecularTarget | 3 |
| hasMolecularTargetClass | 3 |
| hasMolecularTargetType | 3 |
| targetsEnzyme | 3 |
| isTargetOfDrugClass | 2 |
| ligandOf | 2 |
| targetsDrug | 2 |
| targetsMolecule | 2 |
| therapeuticTarget | 2 |
| biologicTarget | 1 |
| drugMechanismStudied | 1 |
| hasPharmacologicalTargetCell | 1 |
| hasPrimaryMolecularTarget | 1 |
| molecularTargetClass | 1 |
| pertuzumabTarget | 1 |
| trastuzumabTarget | 1 |
Description generation (PDg)
The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.
Instruction
Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning. # Instructions Focus on describing the relationship, not the entities themselves. # Response Format Begin the description with \' Indicates...\'
Input
Predicate: hasMolecularTarget
Generated description
Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).
Sample triples (180)
| Subject | Object |
|---|---|
| Xolair | circulating IgE ⓘ |
| REGN-EB3 | Ebola virus glycoprotein GP via predicate surface "targetMolecule" ⓘ |
| CLARITY AD | aggregated amyloid beta via predicate surface "drugTarget" ⓘ |
| EMERGE (Study 302) | amyloid beta via predicate surface "drugTarget" ⓘ |
| Alimta | thymidylate synthase via predicate surface "targetsEnzyme" ⓘ |
| Alimta | dihydrofolate reductase via predicate surface "targetsEnzyme" ⓘ |
| Alimta | glycinamide ribonucleotide formyltransferase via predicate surface "targetsEnzyme" ⓘ |
|
Loxo Oncology
linked to:
Loxo Oncology (acquired)
|
TRK fusion proteins via predicate surface "drugTarget" ⓘ |
|
Loxo Oncology
linked to:
Loxo Oncology (acquired)
|
RET alterations via predicate surface "drugTarget" ⓘ |
|
Loxo Oncology
linked to:
Loxo Oncology (acquired)
|
BTK via predicate surface "drugTarget" ⓘ |
| risdiplam |
SMN2 pre-mRNA
ⓘ
linked to:
SMN2
|
| Tegsedi | TTR gene transcript via predicate surface "molecularTarget" ⓘ |
| SMN2 |
nusinersen
via predicate surface "targetOfDrug"
ⓘ
linked to:
Spinraza
|
| SMN2 | risdiplam via predicate surface "targetOfDrug" ⓘ |
| SMN2 | branaplam via predicate surface "targetOfDrug" ⓘ |
| SMN2 | SMN2-directed antisense oligonucleotides via predicate surface "targetOfDrug" ⓘ |
| MabThera | B cells ⓘ |
| programmed death-ligand 1 |
pembrolizumab
via predicate surface "targetOfDrug"
ⓘ
linked to:
Keytruda
|
| programmed death-ligand 1 | nivolumab via predicate surface "targetOfDrug" ⓘ |
| programmed death-ligand 1 | atezolizumab via predicate surface "targetOfDrug" ⓘ |
| programmed death-ligand 1 |
durvalumab
via predicate surface "targetOfDrug"
ⓘ
linked to:
Imfinzi
|
| programmed death-ligand 1 | avelumab via predicate surface "targetOfDrug" ⓘ |
| andexanet alfa | coagulation factor Xa ⓘ |
| andexanet alfa |
rivaroxaban
ⓘ
linked to:
Xarelto
|
| andexanet alfa | apixaban ⓘ |
| andexanet alfa | edoxaban ⓘ |
| andexanet alfa | enoxaparin ⓘ |
| andexanet alfa |
betrixaban
ⓘ
linked to:
Xarelto
|
| endocannabinoid system | CB1 receptor via predicate surface "ligandOf" ⓘ |
| endocannabinoid system | CB2 receptor via predicate surface "ligandOf" ⓘ |
| Bruton tyrosine kinase |
ibrutinib
via predicate surface "isTherapeuticTargetOf"
ⓘ
linked to:
Imbruvica
|
| Bruton tyrosine kinase | acalabrutinib via predicate surface "isTherapeuticTargetOf" ⓘ |
| Bruton tyrosine kinase | zanubrutinib via predicate surface "isTherapeuticTargetOf" ⓘ |
| Bruton tyrosine kinase | pirtobrutinib via predicate surface "isTherapeuticTargetOf" ⓘ |
| Bruton tyrosine kinase | other BTK inhibitors via predicate surface "isTherapeuticTargetOf" ⓘ |
| HER2 receptor |
trastuzumab
via predicate surface "targetOfDrug"
ⓘ
linked to:
Herceptin
|
| HER2 receptor | pertuzumab via predicate surface "targetOfDrug" ⓘ |
| HER2 receptor | lapatinib via predicate surface "targetOfDrug" ⓘ |
| HER2 receptor | neratinib via predicate surface "targetOfDrug" ⓘ |
| HER2 receptor | tucatinib via predicate surface "targetOfDrug" ⓘ |
| HER2 receptor | ado-trastuzumab emtansine via predicate surface "targetOfDrug" ⓘ |
| HER2 receptor | fam-trastuzumab deruxtecan via predicate surface "targetOfDrug" ⓘ |
| ERBB2 |
trastuzumab
via predicate surface "therapeuticTargetOf"
ⓘ
linked to:
Herceptin
|
| ERBB2 | pertuzumab via predicate surface "therapeuticTargetOf" ⓘ |
| ERBB2 | lapatinib via predicate surface "therapeuticTargetOf" ⓘ |
| ERBB2 | neratinib via predicate surface "therapeuticTargetOf" ⓘ |
| ERBB2 | tucatinib via predicate surface "therapeuticTargetOf" ⓘ |
| ERBB2 | ado-trastuzumab emtansine (T-DM1) via predicate surface "therapeuticTargetOf" ⓘ |
| ERBB2 | fam-trastuzumab deruxtecan via predicate surface "therapeuticTargetOf" ⓘ |
| R-CHOP | CD20 antigen on B cells via predicate surface "targetsMolecule" ⓘ |